FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
Revamping the FDA’s Peptide Panel: A Shift in Expertise
FDA panel on peptides will include – The U.S. Food and Drug Administration (FDA) has announced a new panel of experts for a July meeting focused on reevaluating the safety and efficacy of several peptide-based drugs. This panel, which will convene over two days, includes doctors and pharmacists with significant financial affiliations to the growing industry of unproven chemical therapies. Notably, some of these experts are linked to Health Secretary Robert F. Kennedy Jr., who has publicly endorsed certain peptide injections. This marks a departure from prior panels, which were primarily composed of academic researchers and university-affiliated professionals.
The Rise of Peptide Wellness Trends
Peptides have gained traction as a wellness trend, particularly among athletes, social media influencers, and celebrities. These substances are marketed for a range of benefits, from muscle growth to injury recovery and anti-aging. However, the scientific evidence supporting these claims remains limited. The FDA’s latest panel reflects a broader effort to align health policy with the “Make America Healthy Again” movement, which has been championed by Kennedy and his allies. This shift raises questions about potential conflicts of interest, as industry advocates now hold prominent roles in shaping regulatory decisions.
Previously, the FDA relied on panels of academics and researchers to assess peptide risks. These experts, often from institutions like Duke, Harvard, and Johns Hopkins, had emphasized the need for rigorous testing before approving such compounds. In contrast, the current group features practitioners who are actively involved in the peptide market. Many of them operate clinics or pharmacies that specialize in these products, with some also running online businesses. This composition underscores a growing influence of industry stakeholders in the regulatory process.
Industry Advocacy and Regulatory Challenges
Peptide sellers frequently bypass FDA regulations by classifying their products as “research use only.” This designation allows them to market the substances without requiring full approval, even as they are used for therapeutic purposes. For example, injectable peptides like BPC-157 and TB-500—both of which have been flagged as doping agents by international sports organizations—remain under scrutiny. The FDA has long warned about the risks of these untested compounds, but their popularity continues to rise despite these concerns.
Some of the most vocal supporters of the “Make America Healthy Again” movement are direct sellers of peptide formulas. While pharmaceutical experts argue that these substances should be classified as illegal, unapproved drugs, their proponents claim they offer natural health benefits. The movement’s advocacy has helped legitimize the peptide industry, with its leaders pushing for relaxed regulations to accommodate a wider range of therapeutic options.
Panel Members and Their Industry Roles
Among the new panelists is Dr. Haleem Mohammed, a Florida-based physician who operates clinics specializing in peptide, vitamin, and hormone injections. His practice, part of a national chain called Gameday Men’s Health, sells compounded medications that are not FDA-approved. The company’s website states,
“compounded medications offered through our services are not FDA-approved, and the FDA does not verify their safety.”
This statement highlights the gap between industry claims and regulatory oversight.
Another key figure is Dr. Gabriel Alizaidy, a practitioner who charges $500 for “peptide and hormone” consultations. These sessions, which guide patients on where to source the compounds, are promoted through his social media platforms, including Instagram and TikTok. His website includes a disclaimer:
“each consultation is educational in nature and does not constitute medical care, diagnosis, or treatment.”
This underscores the informal approach some industry advocates take toward patient care.
Bobby Harshbarger, a Tennessee state senator, further illustrates the intersection of politics and peptides. As a pharmacist at his family’s pharmacy, Premiere Pharmacy, Harshbarger has long been associated with the industry. His mother, Rep. Diana Harshbarger, is also a pharmacist and a Republican in Congress. The pair have worked together to advocate for reduced FDA restrictions on peptides. Last year, Diana Harshbarger sent a letter to Kennedy urging him to ease regulations on a group of six peptides, a move that aligns with the broader goals of the movement.
President Donald Trump has previously highlighted Harshbarger’s support for his “Make America Great Again” agenda. This connection is further reinforced by the president’s 2022 pardon of Robert Harshbarger Jr., the senator’s husband. Harshbarger Jr. had pleaded guilty over a decade earlier to substituting an unapproved Chinese drug for one used by dialysis patients. He was stripped of his pharmacy license and served a four-year sentence, which Trump described as a “great example” of justice being done.
The ‘Wild West’ of Peptide Regulation
Peptides have become a cornerstone of the “wild west” of health products, where minimal oversight allows for rapid market growth. Compounding pharmacies play a central role in this ecosystem, creating customized injections that cater to niche demands. These pharmacies often mix ingredients not available through traditional pharmaceutical manufacturers, enabling the production of unapproved therapies. The FDA’s recent decision to include industry-connected experts in its panels suggests a willingness to embrace this decentralized approach.
Despite their widespread use, peptides like BPC-157 and TB-500 remain controversial. The FDA has repeatedly cautioned against their administration without thorough human trials. However, their proponents argue that these substances are safe and effective, citing anecdotal success stories. The upcoming meeting will determine whether these claims gain regulatory traction or if the FDA maintains its cautious stance.
Industry representatives have leveraged the movement to amplify their influence. For instance, the Harshbargers have used their political clout to push for regulatory changes, while figures like Alizaidy and Mohammed have focused on direct consumer engagement. This dual strategy—combining advocacy with market expansion—has helped peptides become a mainstream health option. Yet, the lack of scientific validation for many of their benefits remains a point of contention.
Implications for Health Policy and Public Trust
The inclusion of industry-linked experts in the FDA’s panels signals a potential shift in how regulatory decisions are made. While this approach may streamline the approval process, it could also compromise the agency’s ability to enforce strict safety standards. Critics argue that such a panel risks prioritizing commercial interests over scientific rigor, especially when many of the products in question are marketed with vague or unproven benefits.
As the meeting approaches, the FDA faces pressure to balance innovation with accountability. The panel’s recommendations could redefine the role of peptides in American healthcare, either accelerating their adoption or tightening regulations. The outcome will depend on how the new experts weigh the evidence and whether they can reconcile their industry ties with their duty to protect public health. For now, the “wild west” of peptides continues to thrive, with its advocates pushing for policies that favor accessibility over caution.
Meanwhile, the broader implications of this shift extend beyond peptides. It reflects a growing trend of industry influence in shaping health regulations, raising concerns about transparency and conflict of interest. As the FDA navigates these challenges, the public will be watching closely to see if the panel’s decisions reflect a commitment to scientific integrity or a compromise in favor of market-driven health trends.